The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

被引：441

作者：

Prasit, P

Wang, Z

Brideau, C

Chan, CC

Charleson, S

Cromlish, W

Ethier, D

Evans, JF

Ford-Hutchinson, AW

Gauthier, JY

Gordon, R

Guay, J

Gresser, M

Kargman, S

Kennedy, B

Leblanc, Y

Léger, S

Mancini, J

O'Neill, GP

Ouellet, M

Percival, MD

Perrier, H

Riendeau, D

Rodger, I

Tagari, P

Thérien, M

Vickers, P

Wong, E

Xu, LJ

Young, RN

Zamboni, R

Boyce, S

Rupniak, N

Forrest, N

Visco, D

Patrick, D

机构：

[1] Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada

[2] Merck Res Labs, Harlow, Essex, England

[3] Merck Res Labs, Rahway, NJ 07065 USA

[4] Merck Res Labs, West Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1999年 / 9卷 / 13期

关键词：

D O I：

10.1016/S0960-894X(99)00288-7

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx(R)) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition, (C) 1999 Published by Elsevier Science Ltd. All rights reserved.

引用

页码：1773 / 1778

页数：6